The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients

https://doi.org/10.1007/s10156-012-0449-9Get rights and content

Abstract

There are many limitations to the current antibiotics used for the treatment of severe methicillin-resistant Staphylococcus aureus (MRSA) infections. Ceftaroline is a new fifth-generation cephalosporin approved for the treatment of skin and soft tissue infections caused by MRSA and community-acquired pneumonia. We propose that ceftaroline can also be used successfully in more severe MRSA infections, including endocarditis. We conducted a retrospective chart review in a university-affiliated Department of Veterans Affairs hospital in San Diego, California (USA) of ten inpatients treated with ceftaroline for severe MRSA infection, including five cases of probable endocarditis (including two endocardial pacemaker infections), one case of pyomyositis with possible endocarditis, two cases of pneumonia (including one case of empyema), two cases of septic arthritis (including one case of prosthetic joint infection), and two cases of osteomyelitis. Seven of the 10 patients achieved microbiological cure. Six of the 10 patients achieved clinical cure. Seven patients were discharged from the hospital. Three patients were placed on comfort care and expired in the hospital; one achieved microbiological cure before death, and two remained bacteremic at time of death. In most patients, ceftaroline was effective for treatment of MRSA bacteremia and other severe MRSA infections. Adverse effects seen included rash, eosinophilia, pruritus, and Clostridium difficile infection. Ceftaroline can be a safe and effective drug for treatment of severe MRSA infections, and further comparative studies are warranted.

References (15)

  • CosgroveS.E. et al.

    Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis

    Clin Infect Dis

    (2003)
  • WhitbyM. et al.

    Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis

    Med J Aust

    (2001)
  • StryjewskiM.E. et al.

    Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia

    Clin Infect Dis

    (2007)
  • ChangF.Y. et al.

    Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study

    Medicine (Baltim)

    (2003)
  • FowlerV.G. et al.

    Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

    N Engl J Med

    (2006)
  • Kosowska-ShickK. et al.

    Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae

    Antimicrob Agents Chemother

    (2010)
  • G.R. Corey et al.

    CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

    J Antimicrob Chemother

    (2010)
There are more references available in the full text version of this article.

Cited by (91)

  • Off-label use of ceftaroline fosamil: A systematic review

    2019, International Journal of Antimicrobial Agents
    Citation Excerpt :

    Ceftaroline dose adjustment is indicated for CrCL ≤ 50 mL/min [33]. As reported in Table 1, 12 of the selected studies utilized the 600 mg q8 dose [10,12–16,18,20,26,27,29,31] and three the 800 mg q12 dose [16,20,26] (Table 3). In the case series of bacterial meningitis reported by Sakoulas and colleagues, the only case with unfavorable outcome received a dose of 600 mg q 12 h (the dose approved for ABSSS and CABP) whereas the 4 successful cases received 600 mg q 8 h, indicating a better penetration of CSF at the three times a day (TID) dose [32].

  • Synergistic antibacterial mechanism of Bi <inf>2</inf> Te <inf>3</inf> nanoparticles combined with the ineffective β-lactam antibiotic cefotaxime against methicillin-resistant Staphylococcus aureus

    2019, Journal of Inorganic Biochemistry
    Citation Excerpt :

    Multidrug-resistant (MDR) pathogens pose a substantial threat to public health [1–3]. Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most prevalent MDR pathogens worldwide, causing pneumonia, skin infection, osteomyelitis and bacteremia and exhibiting remarkable resistance to multiple antibiotic treatments [4–8]. However, the development of new antibiotics is vastly outpaced by current therapies that are losing efficacy [9–12].

  • Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli

    2019, Diagnostic Microbiology and Infectious Disease
    Citation Excerpt :

    Trimethoprim-sulfamethoxazole is frequently active in vitro against MRSA; however, it was inferior to vancomycin in a randomized controlled trial of intravenous drug users with severe staphylococcal infections (Markowitz et al., 1992). Ceftaroline is a promising new antibiotic with preliminary data demonstrating efficacy in complicated S. aureus infections; however, there are currently insufficient data to recommend routine use in IE (Casapao et al., 2014; Ho et al., 2012; Lin et al., 2013; Zasowski et al., 2017). Daptomycin in combination with beta-lactams, including ceftaroline, or trimethoprim-sulfamethoxazole may be useful in salvage therapy; however, available outcomes data are limited.

View all citing articles on Scopus
View full text